|
1
|
Jemal A, Murray T, Samuels A, Ghafoor A,
Ward E and Thun MJ: Cancer statistics, 2003. CA Cancer J Clin.
53:5–26. 2003. View Article : Google Scholar
|
|
2
|
Carney DN: Lung cancer - time to move on
from chemotherapy. N Engl J Med. 346:126–128. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bose R and Zhang X: The ErbB kinase
domain: structural perspectives into kinase activation and
inhibition. Exp Cell Res. 315:649–658. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Citri A and Yarden Y: EGF-ERBB signalling:
towards the systems level. Nat Rev Mol Cell Biol. 7:505–516. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takeuchi K and Ito F: EGF receptor in
relation to tumor development: molecular basis of responsiveness of
cancer cells to EGFR-targeting tyrosine kinase inhibitors. FEBS J.
277:316–326. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hirsch FR, Varella-Garcia M, Bunn PA Jr,
et al: Epidermal growth factor receptor in non-small-cell lung
carcinomas: correlation between gene copy number and protein
expression and impact on prognosis. J Clin Oncol. 21:3798–3807.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Baselga J: Targeting tyrosine kinases in
cancer: the second wave. Science. 312:1175–1178. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wakeling AE, Guy SP, Woodburn JR, et al:
ZD1839 (Iressa): an orally active inhibitor of epidermal growth
factor signaling with potential for cancer therapy. Cancer Res.
62:5749–5754. 2002.PubMed/NCBI
|
|
9
|
Van der Veeken J, Oliveira S, Schiffelers
RM, Storm G, van Bergen En Henegouwen PM and Roovers RC: Crosstalk
between epidermal growth factor receptor- and insulin-like growth
factor-1 receptor signaling: implications for cancer therapy. Curr
Cancer Drug Targets. 9:748–760. 2009.PubMed/NCBI
|
|
10
|
Pao W, Miller V, Zakowski M, et al: EGF
receptor gene mutations are common in lung cancers from ‘never
smokers’ and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
|
|
11
|
Kobayashi S, Boggon TJ, Dayaram T, et al:
EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Engelman JA, Zejnullahu K, Mitsudomi T, et
al: MET amplification leads to gefitinib resistance in lung cancer
by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yao Z, Fenoglio S, Gao DC, et al: TGF-beta
IL-6 axis mediates selective and adaptive mechanisms of resistance
to molecular targeted therapy in lung cancer. Proc Natl Acad Sci
USA. 107:15535–15540. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sachdev D and Yee D: The IGF system and
breast cancer. Endocr Relat Cancer. 8:197–209. 2001. View Article : Google Scholar
|
|
15
|
Camirand A, Zakikhani M, Young F and
Pollak M: Inhibition of insulin-like growth factor-1 receptor
signaling enhances growth-inhibitory and proapoptotic effects of
gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res.
7:R570–R579. 2005. View
Article : Google Scholar
|
|
16
|
Pollak MN, Schernhammer ES and Hankinson
SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer.
4:505–518. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Knowlden JM, Jones HE, Barrow D, Gee JM,
Nicholson RI and Hutcheson IR: Insulin receptor substrate-1
involvement in epidermal growth factor receptor and insulin-like
growth factor receptor signalling: implication for gefitinib
(‘Iressa’) response and resistance. Breast Cancer Res Treat.
111:79–91. 2008.PubMed/NCBI
|
|
18
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: the combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Paez JG, Jänne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Su B, Su CX, Zhang HP, Dun QF, Zhao YM and
Zhou CC: Selection and establishment of gefitinib-resistant PC9
cell line and its gene expression profile. Tumor. 28:552–557.
2008.
|
|
22
|
Hewish M, Chau I and Cunningham D:
Insulin-like growth factor 1 receptor targeted therapeutics: novel
compounds and novel treatment strategies for cancer medicine.
Recent Pat Anticancer Drug Discov. 4:54–72. 2009. View Article : Google Scholar
|
|
23
|
Busse D, Doughty RS, Ramsey TT, et al:
Reversible G(1) arrest induced by inhibition of the epidermal
growth factor receptor tyrosine kinase requires up-regulation of
p27(KIP1) independent of MAPK activity. J Biol Chem. 275:6987–6995.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ciardiello F, Caputo R, Bianco R, et al:
Antitumor effect and potentiation of cytotoxic drug activity in
human cancer cells by ZD-1839 (Iressa), an epidermal growth factor
receptor-selective tyrosine kinase inhibitor. Clin Cancer Res.
6:2053–2063. 2000.
|
|
25
|
Jorissen RN, Walker F, Pouliot N, Garrett
TP, Ward CW and Burgess AW: Epidermal growth factor receptor:
mechanisms of activation and signalling. Exp Cell Res. 284:31–53.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Balsara BR, Pei J, Mitsuuchi Y, et al:
Frequent activation of AKT in non-small cell lung carcinomas and
preneoplastic bronchial lesions. Carcinogenesis. 25:2053–2059.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bianco R, Shin I, Ritter CA, et al: Loss
of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells
counteracts the antitumor action of EGFR tyrosine kinase
inhibitors. Oncogene. 22:2812–2822. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cappuzzo F, Toschi L, Tallini G, et al:
Insulin-like growth factor receptor 1 (IGFR-1) is significantly
associated with longer survival in non-small-cell lung cancer
patients treated with gefitinib. Ann Oncol. 17:1120–1127. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dobashi Y, Koyama S, Kanai Y and Tetsuka
K: Kinase-driven pathways of EGFR in lung carcinomas: perspectives
on targeting therapy. Front Biosci. 16:1714–1732. 2011. View Article : Google Scholar : PubMed/NCBI
|
